Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators As Novel Tools for in Vivo Investigation

Overview

Journal ACS Med Chem Lett

Publisher American Chemical Society

Specialty Chemistry

Date 2012 Aug 28

PMID 22924094

Citations 8

Authors

Thomas M Keck

Mu-Fa Zou

Peng Zhang

Rebecca P Rutledge

Amy Hauck Newman

Affiliations

Soon will be listed here.

Abstract

Negative allosteric modulators (NAMs) of metabotropic glutamate receptor subtype 5 (mGluR5) have shown promising results in preclinical models for anxiety and drug abuse. Here we describe a series of aryl-substituted alkynyl analogues of the prototypic mGluR5 NAM 2-methyl-6-(phenylethynyl)pyridine (MPEP, 1). Displacement of [(3)H]1 binding in rat brain membranes showed that several of these novel compounds displayed high affinity binding (K(i) < 10 nM) for mGluR5, with up to a 24-fold increase in affinity over 1. Replacements of the 2-position Me on the pyridyl ring of 1 along with various 3'-CN, 5'-substitutions were generally well tolerated. All of the active analogues in this series had cLogP values in the 2-5 range and displayed inverse agonist characteristics in an ELISA-based assay of G(q)α-mediated IP3 production. Compounds 7i and 7j produced in vivo effects in mouse models of anxiety-like behaviors more potently than 1 or 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP, 2), supporting their utility as in vivo tools.

Citing Articles

Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?.

Budgett R, Bakker G, Sergeev E, Bennett K, Bradley S Front Pharmacol. 2022; 13:893422.

PMID: 35645791 PMC: 9130574. DOI: 10.3389/fphar.2022.893422.

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Lemos A, Melo R, Preto A, Almeida J, Moreira I, Cordeiro M Curr Neuropharmacol. 2018; 16(6):786-848.

PMID: 29521236 PMC: 6080095. DOI: 10.2174/1570159X16666180308161642.

Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.

Caprioli D, Justinova Z, Venniro M, Shaham Y Biol Psychiatry. 2017; 84(3):180-192.

PMID: 29102027 PMC: 5837933. DOI: 10.1016/j.biopsych.2017.08.018.

Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network.

Tassin V, Girard B, Chotte A, Fontanaud P, Rigault D, Kalinichev M Front Neural Circuits. 2016; 10:31.

PMID: 27199672 PMC: 4842779. DOI: 10.3389/fncir.2016.00031.

Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators.

Gregory K, Velagaleti R, Thal D, Brady R, Christopoulos A, Conn P ACS Chem Biol. 2016; 11(7):1870-9.

PMID: 27115427 PMC: 4981245. DOI: 10.1021/acschembio.6b00026.

References

Simon P, Dupuis R, Costentin J . Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res. 1994; 61(1):59-64. DOI: 10.1016/0166-4328(94)90008-6. View

Olive M . Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev. 2009; 2(1):83-98. PMC: 2717506. DOI: 10.2174/1874473710902010083. View

Kulkarni S, Newman A . Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007; 17(7):2074-9. PMC: 1924965. DOI: 10.1016/j.bmcl.2006.12.083. View

Niswender C, Conn P . Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010; 50:295-322. PMC: 2904507. DOI: 10.1146/annurev.pharmtox.011008.145533. View

Anderson J, Bradbury M, Giracello D, Chapman D, Holtz G, Roppe J . In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol. 2003; 473(1):35-40. DOI: 10.1016/s0014-2999(03)01935-6. View

Spooren W, Vassout A, Neijt H, Kuhn R, Gasparini F, Roux S . Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000; 295(3):1267-75. View

Chiamulera C, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M . Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001; 4(9):873-4. DOI: 10.1038/nn0901-873. View

Kulkarni S, Newman A . Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007; 17(11):2987-91. PMC: 1973162. DOI: 10.1016/j.bmcl.2007.03.066. View

Brodkin J, Bradbury M, Busse C, Warren N, Bristow L, Varney M . Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci. 2002; 16(11):2241-4. DOI: 10.1046/j.1460-9568.2002.02294.x. View

10.

Bourin M, Hascoet M . The mouse light/dark box test. Eur J Pharmacol. 2003; 463(1-3):55-65. DOI: 10.1016/s0014-2999(03)01274-3. View

11.

Lindsley C, Bates B, Menon U, Jadhav S, Kane A, Jones C . (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem Neurosci. 2011; 2(8):471-482. PMC: 3172161. DOI: 10.1021/cn100099n. View

12.

Varty G, Grilli M, Forlani A, Fredduzzi S, Grzelak M, Guthrie D . The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl). 2005; 179(1):207-17. DOI: 10.1007/s00213-005-2143-4. View

13.

Alagille D, DaCosta H, Chen Y, Hemstapat K, Rodriguez A, Baldwin R . Potent mGluR5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Bioorg Med Chem Lett. 2011; 21(11):3243-7. PMC: 3826776. DOI: 10.1016/j.bmcl.2011.04.047. View

14.

Kulkarni S, Zou M, Cao J, Deschamps J, Rodriguez A, Conn P . Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. J Med Chem. 2009; 52(11):3563-75. PMC: 2894482. DOI: 10.1021/jm900172f. View

15.

Rocher J, Bonnet B, Bolea C, Lutjens R, Le Poul E, Poli S . mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem. 2011; 11(6):680-95. DOI: 10.2174/1568026611109060680. View

16.

Lindsley C, Emmitte K . Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel. 2009; 12(4):446-57. View

17.

Romano C, Sesma M, McDONALD C, OMalley K, van den Pol A, Olney J . Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995; 355(3):455-69. DOI: 10.1002/cne.903550310. View

18.

Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, Nowak G, Cosford N, Pilc A . Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology. 2004; 47(3):342-50. DOI: 10.1016/j.neuropharm.2004.04.013. View

19.

Busse C, Brodkin J, Tattersall D, Anderson J, Warren N, Tehrani L . The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology. 2004; 29(11):1971-9. DOI: 10.1038/sj.npp.1300540. View

20.

Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R . Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001; 132(7):1423-30. PMC: 1572682. DOI: 10.1038/sj.bjp.0703923. View